PeDRA 2025Abstract 080
ReInspire: A Phase 2 Study of Mutant-Selective PI3Kα Inhibitor, RLY-2608, in Adults and Children with PIK3CA-Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation
Drolet B, Mack J, Sisk B, Al-Huniti A, Chang VY, Hammill A, Iacobas I, Kelly M, McDermott S, Winger BA, Robledo MA, Blakesley R, Patriquin C, Singh S, Crary SE
PeDRA Annual Conference 2025Minneapolis, 9–11 Oct 2025 · published in JID 9 Mar 2026
Topics: Vascular anomaliesPediatric dermatology
Abstract
The abstract’s text is on the JID website.
DOI 10.1016/s0022-202x(26)00613-5 · Not in PubMed: details from Crossref